EA201201457A1 - Органические композиции для лечения заболеваний, связанных с бета-субъединицей эпителиальных натриевых каналов - Google Patents
Органические композиции для лечения заболеваний, связанных с бета-субъединицей эпителиальных натриевых каналовInfo
- Publication number
- EA201201457A1 EA201201457A1 EA201201457A EA201201457A EA201201457A1 EA 201201457 A1 EA201201457 A1 EA 201201457A1 EA 201201457 A EA201201457 A EA 201201457A EA 201201457 A EA201201457 A EA 201201457A EA 201201457 A1 EA201201457 A1 EA 201201457A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- diseases associated
- epitelial
- unit
- sodium channels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
Abstract
В заявке описывают агенты РНКи, применимые в способах лечения заболеваний, связанных с β-ENaC, например муковисцидоза, псевдогипоальдостеронизма типа 1 (ПГА1), синдрома Лиддла, гипертонии, алкалоза, гипокалиемии и гипертонии, связанной с ожирением, используя терапевтически эффективное количество агента РНКи к β-ENaC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32737910P | 2010-04-23 | 2010-04-23 | |
US33339810P | 2010-05-11 | 2010-05-11 | |
PCT/EP2011/056299 WO2011131707A1 (en) | 2010-04-23 | 2011-04-20 | ORGANIC COMPOSITIONS TO TREAT BETA-ENaC-RELATED DISEASES |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201201457A1 true EA201201457A1 (ru) | 2013-04-30 |
EA034363B1 EA034363B1 (ru) | 2020-01-30 |
Family
ID=44227799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201457A EA034363B1 (ru) | 2010-04-23 | 2011-04-20 | Фармацевтическая композиция для ингибирования экспрессии гена beta-enac и ее применение |
Country Status (15)
Country | Link |
---|---|
US (10) | US8344127B2 (ru) |
EP (3) | EP3431604A1 (ru) |
JP (6) | JP5857378B2 (ru) |
KR (4) | KR20180033606A (ru) |
CN (2) | CN102985544A (ru) |
AR (1) | AR081082A1 (ru) |
AU (1) | AU2011244335B2 (ru) |
BR (1) | BR112012027080A2 (ru) |
CA (2) | CA3098080A1 (ru) |
DK (1) | DK2561077T3 (ru) |
EA (1) | EA034363B1 (ru) |
ES (1) | ES2574204T3 (ru) |
MX (1) | MX350595B (ru) |
TW (1) | TWI434692B (ru) |
WO (1) | WO2011131707A1 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3431604A1 (en) | 2010-04-23 | 2019-01-23 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-enac-related diseases |
CN102397279B (zh) * | 2011-11-18 | 2012-10-31 | 新乡医学院 | 无羁萜-3β-醇在制备抗血管性痴呆的药物中的应用 |
SI2852668T1 (sl) * | 2012-07-12 | 2016-09-30 | Proqr Therapeutics Ii B.V. | Oligonukleotidi za izvedbo spremembe v sekvenci tarčne molekule rna, prisotne v živeči celici |
EP3110381B1 (en) | 2014-02-28 | 2020-07-15 | Attends Healthcare Products, Inc. | Absorbent article with multi-layer folded absorbent core |
CN109475552B (zh) * | 2016-08-09 | 2022-04-05 | 上海药苑生物科技有限公司 | 用于食欲控制和体重管理的方法和组合物 |
MX2020012801A (es) | 2018-05-28 | 2021-03-25 | Attends Healthcare Products Inc | Laminado con capa de sequedad para articulos absorbentes. |
CN109364248B (zh) * | 2018-10-16 | 2021-05-18 | 哈尔滨医科大学 | ENaC及其抑制剂在预防、缓解和/或治疗动脉粥样硬化中的应用 |
TW202130809A (zh) * | 2019-10-29 | 2021-08-16 | 美商愛羅海德製藥公司 | 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法 |
US20230136960A1 (en) * | 2020-03-19 | 2023-05-04 | Nature's Toolbox, Inc. | Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same |
CN114149492A (zh) * | 2020-08-21 | 2022-03-08 | 中国人民解放军军事科学院军事医学研究院 | 一种用于预防甲型流感病毒感染的HA-mRNA疫苗 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696561B1 (en) | 1909-07-09 | 2004-02-24 | Basf Aktiengesellschaft | Corynebacterium glutamicum genes encoding proteins involved in membrane synthesis and membrane transport |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
AU2001245793A1 (en) | 2000-03-16 | 2001-09-24 | Cold Spring Harbor Laboratory | Methods and compositions for rna interference |
KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
WO2003070910A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
AU2002364612A1 (en) | 2001-12-31 | 2003-07-24 | Algos Therapeutics, Inc. | METHODS AND MATERIALS FOR MODULATING ENaC-BETA |
US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
WO2004028471A2 (en) | 2002-09-28 | 2004-04-08 | Massachusetts Institute Of Technology | Influenza therapeutic |
EP1560931B1 (en) * | 2002-11-14 | 2011-07-27 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
DE60332277D1 (de) | 2002-11-26 | 2010-06-02 | Univ Massachusetts | Verabreichung von sirnas |
WO2004064731A2 (en) | 2003-01-14 | 2004-08-05 | University Of Washington | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues |
JP2007528712A (ja) * | 2003-07-10 | 2007-10-18 | セノミックス、インコーポレイテッド | ヒトENaCを発現する卵母細胞を用いた改良された電気生理学的アッセイ及び膜電位リポーター色素を用いたアッセイにおけるENaC相乗剤の効果を向上させるためのフェナミルの使用 |
EP1648519B1 (en) | 2003-07-16 | 2014-10-08 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering rna |
EP1660657A1 (en) | 2003-08-28 | 2006-05-31 | Novartis AG | Interfering rna duplex having blunt-ends and 3'-modifications |
WO2005116204A1 (ja) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Rna干渉を生じさせるポリヌクレオチド、および、これを用いた遺伝子発現抑制方法 |
US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
PL2270182T3 (pl) | 2005-09-16 | 2016-07-29 | Devgen Nv | dsRNA jako środek do kontroli owadów |
WO2007051303A1 (en) | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
US7389426B2 (en) | 2005-11-29 | 2008-06-17 | Research In Motion Limited | Mobile software terminal identifier |
GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
EP3045535B1 (en) | 2007-05-22 | 2018-07-25 | Arcturus Therapeutics, Inc. | Methods and uses for therapeutic oligomers |
AR066984A1 (es) | 2007-06-15 | 2009-09-23 | Novartis Ag | Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia) |
AU2008342535B2 (en) | 2007-12-27 | 2015-02-05 | Arbutus Biopharma Corporation | Silencing of polo-like kinase expression using interfering RNA |
EP3431604A1 (en) | 2010-04-23 | 2019-01-23 | Arrowhead Pharmaceuticals, Inc. | Organic compositions to treat beta-enac-related diseases |
-
2011
- 2011-04-20 EP EP18190981.3A patent/EP3431604A1/en active Pending
- 2011-04-20 CA CA3098080A patent/CA3098080A1/en active Pending
- 2011-04-20 KR KR1020187008466A patent/KR20180033606A/ko not_active IP Right Cessation
- 2011-04-20 DK DK11715243.9T patent/DK2561077T3/en active
- 2011-04-20 KR KR1020227000366A patent/KR20220008383A/ko not_active Application Discontinuation
- 2011-04-20 KR KR1020197031212A patent/KR20190122893A/ko not_active Application Discontinuation
- 2011-04-20 ES ES11715243.9T patent/ES2574204T3/es active Active
- 2011-04-20 WO PCT/EP2011/056299 patent/WO2011131707A1/en active Application Filing
- 2011-04-20 CN CN201180030997XA patent/CN102985544A/zh active Pending
- 2011-04-20 AU AU2011244335A patent/AU2011244335B2/en active Active
- 2011-04-20 EP EP11715243.9A patent/EP2561077B1/en active Active
- 2011-04-20 CA CA2797051A patent/CA2797051C/en active Active
- 2011-04-20 JP JP2013505469A patent/JP5857378B2/ja active Active
- 2011-04-20 AR ARP110101377A patent/AR081082A1/es unknown
- 2011-04-20 US US13/090,580 patent/US8344127B2/en active Active
- 2011-04-20 BR BR112012027080A patent/BR112012027080A2/pt not_active Application Discontinuation
- 2011-04-20 CN CN201711213535.7A patent/CN107929306B/zh active Active
- 2011-04-20 MX MX2012012355A patent/MX350595B/es active IP Right Grant
- 2011-04-20 EP EP16163880.4A patent/EP3061824B1/en active Active
- 2011-04-20 KR KR1020127030568A patent/KR20130051954A/ko active Application Filing
- 2011-04-20 EA EA201201457A patent/EA034363B1/ru not_active IP Right Cessation
- 2011-04-22 TW TW100114186A patent/TWI434692B/zh not_active IP Right Cessation
-
2012
- 2012-01-23 US US13/355,879 patent/US8344129B2/en active Active
- 2012-01-23 US US13/355,930 patent/US8344131B2/en active Active
- 2012-01-23 US US13/355,903 patent/US8344130B2/en active Active
- 2012-09-13 US US13/614,836 patent/US8598335B2/en active Active
-
2013
- 2013-10-01 US US14/042,924 patent/US9080175B2/en active Active
-
2014
- 2014-04-17 JP JP2014085797A patent/JP5976032B2/ja active Active
-
2015
- 2015-05-28 US US14/723,555 patent/US9376683B2/en active Active
-
2016
- 2016-05-27 US US15/166,576 patent/US9752152B2/en active Active
- 2016-07-19 JP JP2016141325A patent/JP6290316B2/ja active Active
-
2017
- 2017-07-27 US US15/661,132 patent/US10081811B2/en active Active
-
2018
- 2018-02-07 JP JP2018019887A patent/JP6577073B2/ja active Active
- 2018-08-20 US US16/105,522 patent/US10550391B2/en active Active
-
2019
- 2019-08-21 JP JP2019150816A patent/JP2019214604A/ja active Pending
-
2021
- 2021-10-07 JP JP2021165417A patent/JP2022003089A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201457A1 (ru) | Органические композиции для лечения заболеваний, связанных с бета-субъединицей эпителиальных натриевых каналов | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
CR10347A (es) | Anticuerpos contra el peptidob-amiloide | |
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
CL2013003214A1 (es) | Formulacion estable que comprende al menos un anticuerpo monoclonal que se une especificamente a pcsk9, un tampon, un surfactante y al menos un estabilizador; y su uso para tratar o prevenir enfermedades relacionadas con el colesterol. | |
DK1830881T3 (da) | Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf | |
EA201101190A1 (ru) | Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение | |
UY32989A (es) | Coposiciones terapéuticas concentradas de fosfolípidos | |
EA200901617A1 (ru) | Борсодержащие молекулы небольшого размера | |
EA201290653A1 (ru) | Состав антитела и терапевтические режимы | |
CL2012003656A1 (es) | Uso de una composicion que comprende una enzima de reemplazo para la enzima lisosomal a una concentracion mayor a 5 mg/ml para tratar sintomas somaticos de la deficiencia de la enzima subyacente. | |
CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
EA201200551A1 (ru) | Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения | |
CL2008002111A1 (es) | Compuestos derivados de piridona, agonistas del receptor acoplado a proteina g gpr119; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico, cancer, entre otras. | |
EA201100302A1 (ru) | Лечение диабета у пациентов, для которых лечение метформином является неприемлемым | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BRPI0905369A2 (pt) | Composição farmacêutica, composição e kit compartimentado | |
EA200802247A1 (ru) | Схема дозирования кладрибина для лечения рассеянного склероза | |
UY31136A1 (es) | Oxazolidinonas sustituidas y su uso | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201100921A1 (ru) | Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ | |
EA201190209A1 (ru) | Соединения для лечения метаболических расстройств |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |